Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. / Kronenberg, Florian; Mora, Samia; Stroes, Erik S.G.; Ference, Brian A.; Arsenault, Benoit J.; Berglund, Lars; Dweck, Marc R.; Koschinsky, Marlys L.; Lambert, Gilles; Mach, François; McNeal, Catherine J.; Moriarty, Patrick M.; Natarajan, Pradeep; Nordestgaard, Børge G.; Parhofer, Klaus G.; Virani, Salim S.; von Eckardstein, Arnold; Watts, Gerald F.; Stock, Jane K.; Ray, Kausik K.; Tokgözoğlu, Lale S.; Catapano, Alberico L.

I: Atherosclerosis, Bind 374, 2023, s. 107-120.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Kronenberg, F, Mora, S, Stroes, ESG, Ference, BA, Arsenault, BJ, Berglund, L, Dweck, MR, Koschinsky, ML, Lambert, G, Mach, F, McNeal, CJ, Moriarty, PM, Natarajan, P, Nordestgaard, BG, Parhofer, KG, Virani, SS, von Eckardstein, A, Watts, GF, Stock, JK, Ray, KK, Tokgözoğlu, LS & Catapano, AL 2023, 'Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society', Atherosclerosis, bind 374, s. 107-120. https://doi.org/10.1016/j.atherosclerosis.2023.04.012

APA

Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., von Eckardstein, A., Watts, G. F., Stock, J. K., ... Catapano, A. L. (2023). Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis, 374, 107-120. https://doi.org/10.1016/j.atherosclerosis.2023.04.012

Vancouver

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L o.a. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107-120. https://doi.org/10.1016/j.atherosclerosis.2023.04.012

Author

Kronenberg, Florian ; Mora, Samia ; Stroes, Erik S.G. ; Ference, Brian A. ; Arsenault, Benoit J. ; Berglund, Lars ; Dweck, Marc R. ; Koschinsky, Marlys L. ; Lambert, Gilles ; Mach, François ; McNeal, Catherine J. ; Moriarty, Patrick M. ; Natarajan, Pradeep ; Nordestgaard, Børge G. ; Parhofer, Klaus G. ; Virani, Salim S. ; von Eckardstein, Arnold ; Watts, Gerald F. ; Stock, Jane K. ; Ray, Kausik K. ; Tokgözoğlu, Lale S. ; Catapano, Alberico L. / Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. I: Atherosclerosis. 2023 ; Bind 374. s. 107-120.

Bibtex

@article{811b263b75734347b7770c14715d4316,
title = "Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society",
abstract = "In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: {"}Why should I measure Lp(a) if I can't lower it?{"}. Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.",
keywords = "Atherosclerotic cardiovascular disease, Genetic risk, lipoprotein(a), Risk calculator, Risk factor management",
author = "Florian Kronenberg and Samia Mora and Stroes, {Erik S.G.} and Ference, {Brian A.} and Arsenault, {Benoit J.} and Lars Berglund and Dweck, {Marc R.} and Koschinsky, {Marlys L.} and Gilles Lambert and Fran{\c c}ois Mach and McNeal, {Catherine J.} and Moriarty, {Patrick M.} and Pradeep Natarajan and Nordestgaard, {B{\o}rge G.} and Parhofer, {Klaus G.} and Virani, {Salim S.} and {von Eckardstein}, Arnold and Watts, {Gerald F.} and Stock, {Jane K.} and Ray, {Kausik K.} and Tokg{\"o}zoğlu, {Lale S.} and Catapano, {Alberico L.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.atherosclerosis.2023.04.012",
language = "English",
volume = "374",
pages = "107--120",
journal = "Journal of atherosclerosis research",
issn = "1567-5688",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

AU - Kronenberg, Florian

AU - Mora, Samia

AU - Stroes, Erik S.G.

AU - Ference, Brian A.

AU - Arsenault, Benoit J.

AU - Berglund, Lars

AU - Dweck, Marc R.

AU - Koschinsky, Marlys L.

AU - Lambert, Gilles

AU - Mach, François

AU - McNeal, Catherine J.

AU - Moriarty, Patrick M.

AU - Natarajan, Pradeep

AU - Nordestgaard, Børge G.

AU - Parhofer, Klaus G.

AU - Virani, Salim S.

AU - von Eckardstein, Arnold

AU - Watts, Gerald F.

AU - Stock, Jane K.

AU - Ray, Kausik K.

AU - Tokgözoğlu, Lale S.

AU - Catapano, Alberico L.

N1 - Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: "Why should I measure Lp(a) if I can't lower it?". Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.

AB - In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: "Why should I measure Lp(a) if I can't lower it?". Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.

KW - Atherosclerotic cardiovascular disease

KW - Genetic risk

KW - lipoprotein(a)

KW - Risk calculator

KW - Risk factor management

U2 - 10.1016/j.atherosclerosis.2023.04.012

DO - 10.1016/j.atherosclerosis.2023.04.012

M3 - Review

C2 - 37188555

AN - SCOPUS:85159204299

VL - 374

SP - 107

EP - 120

JO - Journal of atherosclerosis research

JF - Journal of atherosclerosis research

SN - 1567-5688

ER -

ID: 360066193